Affimed N.V. (AFMD)

DE — Healthcare Sector
Peers: TCRR  PIRS  ADCT  AGEN  XFOR  TERN  DAWN  PDSB  INZY  LPTX  ADAP  CRVS  APTO  EFTR  ELEV  MREO  HEPA 

Automate Your Wheel Strategy on AFMD

With Tiblio's Option Bot, you can configure your own wheel strategy including AFMD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol AFMD
  • Rev/Share 0.0545
  • Book/Share 1.068
  • PB 0.1495
  • Debt/Equity 0.7496
  • CurrentRatio 1.9306
  • ROIC -2.4461

 

  • MktCap 2616690.159
  • FreeCF/Share -4.8098
  • PFCF -0.0338
  • PE -0.0367
  • Debt/Assets 0.3226
  • DivYield 0
  • ROE -1.9385

 

  • Rating
  • Score
  • Recommendation
  • P/E Score
  • DCF Score
  • P/B Score
  • D/E Score

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Downgrade AFMD H.C. Wainwright Buy Neutral -- -- May 14, 2025
Downgrade AFMD Leerink Partners Outperform Market Perform -- -- May 13, 2025

News

Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement
AFMD
Published: April 21, 2025 by: GlobeNewsWire
Sentiment: Neutral

MANNHEIM, Germany, April 21, 2025 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it has received a written notice (the “Notice”), dated April 15, 2025, from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that, for the last thirty (30) consecutive business days, the bid price for the Company's common shares had closed below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Rule”).

Read More
image for news Affimed Announces Receipt of NASDAQ Deficiency Notice Regarding Minimum Bid Price Requirement

About Affimed N.V. (AFMD)

  • IPO Date 2014-09-12
  • Website https://www.affimed.com
  • Industry Biotechnology
  • CEO Dr. Shawn M. Leland Pharm.D., R.Ph.
  • Employees 76

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in Phase I clinical trial for hodgkin lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia; and AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. Affimed N.V. has collaboration agreements with The University of Texas MD Anderson Cancer Center; Genentech, Inc.; and Roivant Sciences Ltd., as well as research funding agreement with The Leukemia & Lymphoma Society. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany.